Orforglipron (Foundayo)

Orforglipron (brand name Foundayo) is an FDA-approved oral, non-peptide GLP-1 receptor agonist and the first small-molecule GLP-1 approved for weight management. Approved April 2026 under the FDA's National Priority Voucher program, Foundayo can be taken once daily at any time without food or water restrictions. Clinical trials demonstrated up to 11.1% weight loss (24.9 lbs) at 72 weeks with the highest approved dose (17.2mg) and robust glycemic control (HbA1c reductions of 1.3-1.6%). Developed by Chugai Pharmaceutical and marketed by Eli Lilly. Available in 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg tablets.

• Obesity Management Without Diabetes
• Obesity Management With Type 2 Diabetes
• Cardiometabolic Risk Factor Improvement

FDA-approved for weight loss (up to 11.1% at 72 weeks), robust diabetes control (HbA1c reduction 1.3-1.6%), once-daily oral tablet taken any time of day, no refrigeration or food/water restrictions, reduced cardiovascular risk markers, available as low as $25/month with insurance

Small-molecule GLP-1 receptor agonist with biased signaling - preferentially activates G protein/cAMP pathways (enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite) while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life supporting once-daily dosing.

Peak plasma concentration: 8 hrs. Elimination half-life: 1.2 days – 2.0 days. Largely cleared by: 6.0 days – 10.2 days.

Research protocols from published literature — not dosing recommendations.

• Semaglutide — Avoid Combination: Both are GLP-1 agonists - combining increases risk of severe hypoglycemia and excessive GI side effects including intractable nausea and vomiting
• Tirzepatide — Avoid Combination: Dual GIP/GLP-1 agonist overlaps with GLP-1 mechanism - combination contraindicated due to additive hypoglycemic effects and severe GI toxicity
• Liraglutide — Avoid Combination: Another GLP-1 agonist - concurrent use contraindicated due to overlapping mechanisms and compounded adverse effects
• Insulin — Monitor Combination: Orforglipron enhances insulin sensitivity - may require significant insulin dose reduction to prevent hypoglycemia, requires close monitoring
• Metformin — Synergistic: Complementary mechanisms for diabetes management - Phase 3 trials combining orforglipron with metformin showed enhanced efficacy without increased adverse events
• Dapagliflozin — Compatible: SGLT-2 inhibitor with distinct mechanism - combination being evaluated in Phase 3 ACHIEVE-2 trial for potential additive metabolic benefits
• CJC-1295 — Compatible: Growth hormone secretagogue may help preserve lean muscle mass during GLP-1-induced weight loss without interaction concerns
• Ipamorelin — Compatible: May help maintain metabolic rate and muscle preservation during caloric restriction from orforglipron therapy
• BPC-157 — Compatible: No known interactions - may theoretically support gut health and potentially mitigate GI side effects common with GLP-1 agonists
• 5-Amino-1MQ — Compatible: NNMT inhibition mechanism is distinct from GLP-1 pathway - may complement metabolic effects for enhanced optimization

Week 1-2: Appetite reduction typically within 1-3 days of first dose, Mild to moderate nausea common (usually improves significantly), Diarrhea possible (19-26% of patients) - stay well hydrated. Week 2-4: Gradual weight loss begins (0.5-2 lbs per week), Improved blood sugar control within 1-4 weeks for diabetic patients, GI side effects generally diminish after first month. Week 4-12: Reduced food cravings and enhanced satiety throughout the day, Energy levels normalize after initial adaptation period, Improved metabolic markers (blood pressure, lipids) become evident. Week 12-36: Continued progressive weight loss without plateau, Peak weight loss effects typically seen at 36-72 weeks, Sustained improvements in cardiovascular risk factors. Week 36+: Long-term therapy well-tolerated in clinical trials, Participants show sustained benefits without plateau at 72 weeks, Ongoing diabetes prevention and metabolic health improvements.

BOXED WARNING: May cause thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Contraindicated in patients with personal/family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Start at 0.8mg daily, titrate to 2.5mg after 30 days, then 5.5mg after 60 days - gradual titration minimizes GI side effects. Do not use with other GLP-1 receptor agonist medicines. Monitor for signs of acute pancreatitis (severe, persistent abdominal pain with or without nausea/vomiting) - stop taking Foundayo immediately if suspected. Common side effects: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss. May cause dehydration leading to kidney problems - drink fluids to reduce risk, especially with nausea/vomiting/diarrhea. May affect oral contraceptive efficacy - use alternative birth control for 30 days after starting and after each dose increase. May require adjustment of insulin or sulfonylurea doses to prevent low blood sugar (hypoglycemia). Not safe during pregnancy (may harm unborn baby) or breastfeeding - pregnancy exposure registry available at 1-800-LillyRx. Gallbladder problems reported - monitor for upper abdominal pain, fever, jaundice, or clay-colored stools. Tell healthcare providers you take Foundayo before any surgery or procedure using anesthesia (aspiration risk). If doses missed for 7+ consecutive days, contact healthcare provider about how to restart treatment.

BOXED WARNING: May cause thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Contraindicated in patients with personal/family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Start at 0.8mg daily, titrate to 2.5mg after 30 days, then 5.5mg after 60 days - gradual titration minimizes GI side effects. Do not use with other GLP-1 receptor agonist medicines. Monitor for signs of acute pancreatitis (severe, persistent abdominal pain with or without nausea/vomiting) - stop taking Foundayo immediately if suspected. Common side effects: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss. May cause dehydration leading to kidney problems - drink fluids to reduce risk, especially with nausea/vomiting/diarrhea. May affect oral contraceptive efficacy - use alternative birth control for 30 days after starting and after each dose increase. May require adjustment of insulin or sulfonylurea doses to prevent low blood sugar (hypoglycemia). Not safe during pregnancy (may harm unborn baby) or breastfeeding - pregnancy exposure registry available at 1-800-LillyRx. Gallbladder problems reported - monitor for upper abdominal pain, fever, jaundice, or clay-colored stools. Tell healthcare providers you take Foundayo before any surgery or procedure using anesthesia (aspiration risk). If doses missed for 7+ consecutive days, contact healthcare provider about how to restart treatment.

Orforglipron (Foundayo) should be stored at Room temperature (15-30°C), no refrigeration required.